Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 83,194

Document Document Title
WO/2018/006643A1
Provided is a traditional Chinese medicine for providing a man with kidney-tonifying, blood circulation-promoting and liver-soothing benefits. The traditional Chinese medicine consists of the following raw materials: 15-25 g of Salvia mi...  
WO/2018/006646A1
Provided is a decoction for tonifying the kidney, promoting the blood circulation and soothing the liver. The decoction is prepared with Radix bupleuri, white peony root, Cuscuta chinensis, Acorus gramineus, Eucommia ulmoides, Angelica s...  
WO/2018/006641A1
Provided is a traditional Chinese medicine for treating the edema caused by spleen deficiency with damp harassment in pregnant women. The traditional Chinese medicine is prepared by mixing the following raw materials in parts by weight: ...  
WO/2018/006642A1
Provided is a TCM drug for treating pregnant women suffering from spleen deficiency and dampness stagnation. The TCM drug consists of the following raw materials: 15-30 g of Radix scrophulariae, 10-25 g of Atractylodes macrocephala, 20-3...  
WO/2018/006645A1
Provided is a decoction for soothing the liver and tonifying the kidney. The decoction is prepared with 8-12 g of Radix bupleuri, 7-14 g of white peony root, 8-12 g of Cuscuta chinensis, 6-14 g of Acorus gramineus, 4-8 g of Concha Meretr...  
WO/2018/008569A1
Provided is an industrially advantageous method for producing a compound (1), specifically a compound (1) in an amorphous form. A method for producing a calcium salt of a 1, 5-benzodiazepine compound represented by formula (1), which is ...  
WO/2018/009867A1
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, and R6, R11a, and R11b are as defined herein. Compounds of the present invention...  
WO/2018/008749A1
A nucleic acid which can inhibit expression of the MEX3B gene with low cytotoxicity as a side effect, an MEX3B gene expression inhibitor which contains said nucleic acid, a method for inhibiting MEX3B gene expression, and a prophylactic ...  
WO/2018/001391A1
The present invention discloses an innovate and safe method for effective and safe treatment of peripheral diabetic polyneuritis, tendinopathies, and gingivitis - periodontitis, via the topical administration of the gynura procumbens oil...  
WO/2018/000688A1
Disclosed are a traditional Chinese medicine oral liquid for treating insufficiency of qi and blood, and a preparation method therefor. The oral liquid is prepared from the following main raw materials in proportion by weight: 5-10 parts...  
WO/2018/005700A1
Provided herein are specific dosages and dosage schedules of a composition comprising at least one gluten peptide for use in treating subjects with Celiac disease.  
WO/2018/002738A1
The present invention provides a taste masked liquid pharmaceutical composition of an active pharmaceutical ingredient, (RS)-4-(ethyl[1-(4- methoxyphenyl)propan-2-yl]amino)butyl 3,4-dimethoxybenzoate or pharmaceutically acceptable salts ...  
WO/2018/003134A1
This composition for use in the oral cavity is characterized by containing scutellaria root, cinnamon, and hoelen. When the content of scutellaria root in the composition for use in the oral cavity is taken as XA [mass%] and the content ...  
WO/2018/005427A1
Methods for preventing esophageal stricture following an endoscopic resection procedure in a subject are provided. A solution having a pH level of about 3.5 and including a self-assembling peptide comprising between about 7 amino acids a...  
WO/2018/003531A1
The present invention provides a pyrroloquinone quinone monosodium having a structure represented by formula (1).  
WO/2018/002897A1
The present invention concerns compounds having formula (I) and compositions thereof with a pharmacologically acceptable excipient and uses thereof as a medicament, in particular for the treatment and/or prevention of a disorder selected...  
WO/2018/002155A1
The present invention provides novel compounds that target thrombocyte activity or aggregation capacity through cellular components for the treatment of diseases associated with Non-Alcoholic Fatty Liver Disease (NAFLD). The invention pr...  
WO/2018/002018A1
The invention relates to a composition containing ectoine, hydroxyectoine and/or salts, esters or amides of said compounds as an active substance for use in a method for the treatment and/or prevention of gastroesophageal reflux diseases...  
WO/2018/001273A1
Provided are a peptide or a salt thereof, and a preparation method therefor. The peptide may be selected from VVYP, AVLP, IGFP, LLIIVP and STAP. The preparation method comprises steps as follows: using a resin as a starting material, lin...  
WO/2018/002671A1
A composition for the treatment and/or nutrition of poultry such as broiler chickens is disclosed as comprising (i) one more probiotics which are commensal selected from one or more of Bifidobacterium animalis, Collinsella tanakaei, Lact...  
WO/2018/003997A1
The present invention addresses the problem of providing a safe and easy-to-prepare cell preparation for prevention and/or treatment of organ fibrosis such as liver fibrosis. Provided is a cell preparation for prevention and/or treatment...  
WO/2018/000690A1
A traditional Chinese medicine oral liquid for treating insufficiency of qi and blood is prepared from the following main raw materials in parts by weight: 5-10 parts of Panax ginseng, 4-9 parts of Saussurea involucrate, 10-20 parts of T...  
WO/2018/000689A1
A traditional Chinese medicine beverage for treating liver-qi stagnation and a preparation method therefor. The traditional Chinese medicine beverage comprises the following main raw materials: acorus calamus, Ligustrum lucidum Ait, Clem...  
WO/2017/220044A2
Disclosed are a bifonazole pharmaceutical composition and a liver-protecting effect thereof. The bifonazole pharmaceutical composition contains bifonazole and a natural product compound (I) separated from dried fritillaria thunbergii bul...  
WO/2017/223273A1
In certain aspects, described herein are methods, bacteria, and compositions for the reduction of the amount, activity and/or proliferation of colonic group 3 innate lymphoid cells (ILC3s) and for the treatment and/or prevention of disea...  
WO/2017/219935A1
The present invention discloses a biaryl urea RORγt inhibitor, and specifically relates to a biaryl urea derivative, as represented by formula I, with an RORγt inhibiting activity, and a manufacturing method thereof, and a pharmaceutic...  
WO/2017/221142A1
The present disclosure relates to a Wingless-type (wnt) inhibitor of formula (I) for use in the treatment of fibrosis and some fibrosis mediated disorders such as stiff skin syndrome and systemic sclerosis. The present disclosure also pr...  
WO/2017/221886A1
Provided are an intestinal environment-improving agent containing as an active ingredient a compound represented by formula [I] or a pharmaceutically acceptable salt thereof, and a novel medicine useful in the prevention or treatment of ...  
WO/2017/221083A1
The compositions and compounds of formula I which includes ribavirin conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These conjugates may be formulated as pharmaceutical compositions. The pharmac...  
WO/2017/219835A1
Disclosed is an anti-bacterial and anti-inflammatory mouthwash, mainly composed of deionized water, and at least added to with a combination of a tranexamic acid, chlorogenic acid, Andrographis paniculata extract and honeysuckle extract....  
WO/2017/221799A1
The problem is solved by an upper gastrointestinal flora-improving agent, the agent containing lactobacilli as an active ingredient, to be used in persons positive and negative for Helicobacter pylori. Lactobacilli of the genus Lactobaci...  
WO/2017/221879A1
The present invention addresses the problem of providing: a trophic factor release agent which makes it possible to increase the quantity of a trophic factor released from cells in a cell transplantation therapy or the like; and an infla...  
WO/2017/219915A1
A phosphonate prodrug for an adenine derivative, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. The compound can be used in the preparation of drugs for treating virus infective diseases, especi...  
WO/2017/218894A1
Suspensions of pump inhibitors (PPIs) are disclosed. The suspension may include a PPI, a copolymer of ethylene oxide and propylene oxide; simethicone emulsion; Sodium Bicarbonate; and Sodium Citrate, USP (Dihydrate). The suspensions have...  
WO/2017/216576A1
The invention relates to difluoro heterocyclic compounds and their medical uses. Compounds of the invention have the general formula (I): wherein each X is identical and forms part of an ethoxyamine basic side chain which includes a 5- o...  
WO/2017/215676A1
A carbidopa pharmaceutical composition and medical use thereof for treating liver cancer are provided. The carbidopa pharmaceutical composition provided in the present invention comprises carbidopa and a naturally produced compound (I) h...  
WO/2017/218330A1
The present disclosure relates generally to compounds (I) which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment...  
WO/2017/215349A1
Disclosed is a use of a mogrol in the preparation of drugs and/or health care products for treating and/or preventing hepatic fibrosis. In vivo and in vitro experiments demonstrate that mogrol can significantly improve the extent of in v...  
WO/2017/217326A1
The purpose of the present invention is to provide a diarrhea-preventing nutritional composition that enables the ingestion or administration of nutritional components while effectively preventing diarrhea and that can maintain a stable ...  
WO/2017/216579A1
The invention relates to a heterocyclic compound 1,1'-(((propane-2,2-diylbis(4,1-phenylene))bis(oxy))bis(etha ne-2,1-diyl))dipyrrolidine and its medical uses, for example as an autophagy inducer.  
WO/2017/216088A1
The present invention relates to a multiple unit dosage form comprising a core, wherein the core comprises a plurality of individual units, each unit comprising a pharmaceutically active ingredient and each unit being covered with a muco...  
WO/2017/216813A1
The invention relates to a composition to reduce DNA and hepatic damage and to enhance repair thereof. More particularly the invention relates to a synergistic composition comprising combination of active ingredients which can be used in...  
WO/2017/217556A1
The purpose of the present invention is to provide a medicine for preventing or treating TGFβ-related diseases by inhibiting signal transduction of TGFβ. Provided are: a TGFβ inhibitor that contains, as an active ingredient, the REIC/...  
WO/2017/218337A1
The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of ...  
WO/2017/218421A1
Pharmaceutical compositions and methods of treatment or prevention of diseases and conditions associated with or characterized by at least one of xerostomia and periodontal disease by modulation of the nitric oxide synthase pathway are p...  
WO/2017/216165A1
The present disclosure is related to pharmaceutical compositions and methods for treating and/or preventing oxalate-related disorders. More particularly, the present disclosure pertains to compositions comprising an oxalate- degrading ba...  
WO/2017/213076A1
The present invention relates to an absorption promoter for S-allyl cysteine (SAC) and alliin, including garlic egg yolk.  
WO/2017/211617A1
The present invention relates to a compound for use as a medicament in the treatment or prevention of acute liver failure, which acute liver failure is induced by intoxication prior to or following administration of the compound. Accordi...  
WO/2017/212433A1
The present invention relates to the use of a composition based on bacteria and/or yeasts and/or other microorganisms, taken singularly or in combination, for the treatment of the symptoms of and/or for treating Irritable Bowel Syndrome ...  
WO/2017/214383A1
Methods for the treatment or prevention of disease, such as fatty liver disease and obesity, are described including the modulation the amount of CTRP1 in a subject. Novel mouse strains are also described.  

Matches 1 - 50 out of 83,194